HC Wainwright & Co. Reiterates Buy on Spruce Biosciences, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Spruce Biosciences (NASDAQ:SPRB) and maintained a $10 price target.
June 13, 2023 | 10:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms Buy rating on Spruce Biosciences (NASDAQ:SPRB) and keeps $10 price target.
The reiteration of the Buy rating and maintenance of the $10 price target by HC Wainwright & Co. analyst Raghuram Selvaraju indicates a positive outlook for Spruce Biosciences. This news is likely to have a positive short-term impact on the stock price as it shows continued confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100